Thymosin Beta-4 (TB4) and TB-500 are often referenced interchangeably in peptide research discussions, but they are not the same molecule. The distinction matters for experimental design, dosing calculations, and result interpretation — and the confusion between them is one of the most common sources of error in the field.
What is Thymosin Beta-4?
Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide found in virtually all mammalian cell types. It was first isolated from calf thymus tissue in the 1960s as part of a broader effort to characterize thymic hormones. TB4 primary intracellular role is as a major actin-sequestering protein — it binds monomeric G-actin and prevents its polymerization into F-actin filaments, playing a critical role in cytoskeletal dynamics, cell migration, and wound healing.
Beyond its cytoskeletal function, TB4 has demonstrated anti-inflammatory, anti-apoptotic, and pro-angiogenic properties in preclinical models. It promotes cell migration and survival, stimulates collagen deposition, and modulates inflammatory cytokine expression. These properties have made it a subject of extensive research in tissue repair, cardiac injury, corneal wound healing, and dermal regeneration.
What is TB-500?
TB-500 is a synthetic peptide fragment that corresponds to the active region of Thymosin Beta-4. Specifically, it consists of the amino acid sequence at positions 17-23 of the full TB4 molecule (the actin-binding domain), sometimes extended to include flanking residues for stability. It is NOT the full-length protein — it is a fragment designed to replicate the key biological activity of the parent molecule at a lower molecular weight and potentially improved tissue penetration.
The name “TB-500” is a commercial designation, not a formal biochemical nomenclature. In the literature, you will find references to “TB4 active fragment,” “Tβ4(17-23),” and similar designations that all describe the same molecular concept. The marketplace has largely standardized on “TB-500” for the fragment and “Thymosin Beta-4” or “TB4” for the full-length peptide.
Key Differences for Researchers
The most important difference is molecular weight and structure. TB4 is 4,921 daltons (43 amino acids); TB-500 is approximately 750-900 daltons (7-9 amino acids depending on the exact fragment). This size difference has implications for tissue penetration, half-life, and receptor binding kinetics.
In practice, many of the observed biological activities attributed to TB4 in the literature have been replicated with the TB-500 fragment, particularly those related to actin binding and cell migration. However, the full-length peptide contains additional functional domains that the fragment does not — including regions involved in nuclear localization and gene regulation. Research protocols that depend on these non-actin-binding functions should use the full-length TB4.
Choosing Between Them
For research focused on wound healing, tissue repair, and cell migration — the most common applications — TB-500 is generally the more practical choice. It is more cost-effective to synthesize, easier to handle, and the actin-binding domain it represents is the primary driver of the therapeutic effects observed in most preclinical studies.
For research that requires the full complement of TB4 biological activities, or for studies that aim to characterize the complete signaling profile of the molecule, the full-length Thymosin Beta-4 is necessary. We carry both at Universal Amino Goods precisely because different research programs have different requirements.
Handling Notes
Both compounds should be stored lyophilized at negative twenty degrees Celsius. TB-500, being a smaller fragment, is generally more stable in solution — reconstituted vials maintain activity for four to six weeks at two to eight degrees Celsius. Full-length TB4 is somewhat more susceptible to degradation and should be used within three to four weeks of reconstitution. Both should be reconstituted with bacteriostatic water.
Whichever form you choose, verify the identity through your certificate of analysis. Mass spectrometry should confirm the expected molecular weight, and HPLC purity should be ninety-eight percent or higher. Knowing exactly what molecule is in your vial is the first step toward reproducible results.